What is CommonQuant (Common Quant)?

CommonQuant, also written Common Quant, is an AI-powered trading platform that turns plain-English market ideas into live, rules-based strategies. It selects relevant instruments, writes indicator-based entry and exit rules, monitors the conditions continuously, and alerts users when conditions are met.

How does CommonQuant generate trading strategies?

You write a natural-language prompt describing your market idea. CommonQuant selects validated instruments, chooses from 20 supported technical indicators, and writes concrete entry and exit rules. The strategy then runs live and sends alerts through the channels available on your plan when conditions trigger.

What markets and instruments does CommonQuant support?

CommonQuant supports several thousand US equities and ETFs listed on Nasdaq, NYSE, NYSE American, and Cboe, plus major crypto assets such as Bitcoin. It does not support FX or futures.

How do I receive trading signal alerts?

CommonQuant provides an in-app signal inbox on all plans. Paid plans add email and Telegram, plus metered monthly SMS and WhatsApp allowances. Channel availability and allowances vary by plan.

Is CommonQuant free to use?

Yes. CommonQuant has a free tier with 1,000 starter credits, 200 monthly refill credits, up to three signal subscriptions, and in-app alerts. Paid plans start at $9/month, and no credit card is required to start.

Does CommonQuant provide financial advice?

No. CommonQuant is a quantitative tool for alpha validation and does not constitute financial advice. Past performance does not guarantee future results. Users are responsible for their own trading decisions.

Can I copy public trading strategies?

Yes. Users can browse, preview, and copy public community and AI-generated strategies into their own accounts. They can also follow strategists and take part in Arena competitions.

CommonQuant.ai Research

AI-generated trading idea · SHORT · ADMA

Biotech hit with federal lawsuit over fake revenue — short the crash

ADMA Biologics just got hit with a federal lawsuit accusing the company of artificially inflating its revenue numbers.

Idea

Lawsuits alleging fake revenue numbers almost always trigger a panic sell-off as investors run for the exits to avoid the unknown. Even if the company eventually defends itself, the stock price usually gets dragged down by the bad headlines and uncertainty in the short term. This makes it a prime candidate to bet against as the selling pressure builds.

Key details

ADMA1H#stock#legal#momentum

Community

Upvotes

Views

Copies

Cosigns

News sources

ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations — Yahoo Finance

Related ideas

Massive $5.4 billion floods into chip stocks — ride the wave on SOXX
Nvidia tanks $1 trillion as panic selling hits tech — contrarian bounce play on the AI king
Trillion-dollar chip giant SK Hynix hits Wall Street — ride the IPO momentum

ADMA trade ideas
Latest market news